Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma
Status:
Not yet recruiting
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn about how a combination of tazemetostat and
venetoclax in people with relapsed/refractory Non-Hodgkin Lymphoma (R/R NHL). The main
questions that this trial aims to answer are what is the best dose of venetoclax to give with
tazemetostat to people with R/R NHL; what types of side effects do people with R/R NHL get
when taking venetoclax with tazemetostat; and what effects does this combination have on R/R
NHL. Participants will need to take pills by mouth every day and regularly come to the clinic
for blood work and imagining to monitor side effects and cancer progression. Participants may
receive study drugs for up to 24 months.